Johnson & Johnson — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 28, 2014. The filing is an annual report, not a standalone fourth-quarter report; it provides selected Q4 repurchase information. Johnson & Johnson operated through more than 265 companies in over 60 countries, with approximately 126,500 employees, across Consumer, Pharmaceutical and Medical Devices.
Financial performance and key metrics
The supplied filing text incorporates the audited financial statements and management’s discussion by reference to the 2014 Annual Report, but does not include their contents. As a result, clear values for consolidated revenue, profit, cash flow, margins, debt and liquidity are not provided here.
- Worldwide R&D expense was $8.5 billion in 2014, compared with $8.2 billion in 2013 and $7.7 billion in 2012.
- REMICADE accounted for approximately 9.2% of 2014 total revenue.
- The company authorized up to $5.0 billion in share repurchases in July 2014. By December 28, 2014, it had purchased 33.7 million shares for $3.5 billion under that program, with approximately 14.3 million shares remaining under the authorization.
- During fiscal Q4, the company repurchased 26.2 million shares in total: 16.6 million under the announced program and 9.6 million through open-market purchases for compensation-program needs.
Changes versus prior periods
- R&D spending increased approximately 4% from 2013 and 10% from 2012, based on the reported figures.
- The Ortho-Clinical Diagnostics business was divested in June 2014; the divestiture also resulted in the sale of eight manufacturing facilities.
- Medical Devices was previously referred to as Medical Devices and Diagnostics.
Outlook, commentary, risks and unusual items
- The supplied text contains no clear numerical earnings or revenue guidance. Management’s discussion and outlook are incorporated by reference but not reproduced.
- The company identified patent challenges and potential biosimilar competition for REMICADE. It stated that loss of exclusivity would likely reduce sales; U.S. patent proceedings were ongoing, and certain patent claims had been invalidated or were under review in other jurisdictions.
- McNeil Consumer Healthcare facilities remained subject to an FDA consent decree and remediation oversight. In February 2015, a third-party expert submitted certifications for three sites; the timing of any FDA inspection was at the FDA’s discretion.
- Other cited risks include increasingly stringent regulation, pricing and payer pressure, product safety and recall exposure, complex global supply chains, international political and economic uncertainty, and competition requiring continued R&D and marketing investment.
- In Q4 2014, a subsidiary settled a California hazardous-waste handling claim, agreeing to remedial actions and a payment of approximately $400,000.
- The company reported no significant overall sales seasonality, but spending was typically heavier in Q4, principally for advertising and R&D.
Important facts for investors to verify
- Consult the incorporated 2014 Annual Report for audited revenue, earnings, cash flow, segment performance, balance-sheet, debt, liquidity and management outlook details; those figures are not present in the supplied text.
- Review the full disclosures on REMICADE patent litigation, biosimilar timing and the potential sales impact.
- Check the status and financial implications of the McNeil consent decree and FDA review of the facility certifications.
- Assess the Ortho-Clinical Diagnostics divestiture’s effect on continuing operations and comparability.
- Review the full legal proceedings and contingencies disclosures incorporated from Note 21 of the Annual Report.